Identification of a Novel Human Cancer/Testis Antigen, KM-HN-1, Recognized by Cellular and Humoral Immune Responses
Purpose: We used serologic screening of a cDNA expression library of human testis to identify novel cancer/testis antigens that elicit both humoral and cellular immune responses in cancer patients. Experimental Design and Results: We identified a novel gene designated KM-HN-1 the expression of which...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2004-09, Vol.10 (18), p.6047-6057 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: We used serologic screening of a cDNA expression library of human testis to identify novel cancer/testis antigens that elicit
both humoral and cellular immune responses in cancer patients.
Experimental Design and Results: We identified a novel gene designated KM-HN-1 the expression of which is testis-specific among normal tissues; it contains coiled coil domains and a leucine zipper motif
and encodes a putative protein consisting of 833 amino acids. KM-HN-1 expression was observed in various cancer tissues and
cancer cell lines at both mRNA and protein levels. Immunofluorescence staining of an esophageal cancer cell line revealed
that KM-HN-1 protein was present exclusively in the nucleus during mitosis. Recombinant KM-HN-1 protein was produced, and
used for ELISA to quantitate levels of IgG antibody specific to KM-HN-1. Higher levels of IgG antibodies specific to KM-HN-1
were detected in many types and numbers of cancer patients but not in healthy donors. The CTL lines specific to KM-HN-1, generated
from HLA-A * 2402– positive healthy donors and cancer patients, killed human leukocyte antigen (HLA)-A24-positive cancer cells expressing KM-HN-1
but not cell lines that did not express either KM-HN-1 or HLA-A24.
Conclusions: We identified a novel cancer/testis antigen, KM-HN-1, which elicited humoral immune responses in patients with various types
of cancer. Furthermore, KM-HN-1-specific CTLs could be generated from both healthy donors and cancer patients, which indicated
that KM-HN-1 can be a candidate for an ideal target for cancer immunotherapy. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-04-0475 |